Advanced malignant solid tumors
Conditions
Interventions
The cohort of receiving immune checkpoint inhibitor:NA
Sponsors
The 960th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult patients >=18 years old; 2. Patients with a clear histopathological diagnosis of tumor cases; 3. Receiving immune checkpoint inhibitor therapy alone or in combination with chemotherapy. 4. The ECOG-PS score is 0-2; 5. Receiving continuous anti-tumor therapy for >=2 cycles; 6. There is at least one measurable target lesion according to the modified criteria for the evaluation of solid tumor efficacy; 7. The patient's medical records and follow-up information are complete.
Exclusion criteria
Exclusion criteria: 1. Pathological diagnosis and disease stage do not meet the inclusion criteria. 2. Receiving immunotherapy for no more than 2 cycles; 3. Primary tumors; 4. Undergoing surgery or other invasive procedures in the past or during immunotherapy; 5. Participating in clinical trials. 6. The patient has autoimmune diseases or progressive cardiovascular and digestive diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival;Area Under the Receiver Operating Characteristic Curve (AUC-ROC);Accuracy;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactJinmin Guo
The 960th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Outcome results
None listed